drugset / Trial / NCT07404137

A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

NCT07404137

Phase 1 Completed 26 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate the concentrations of zibotentan and dapagliflozin in blood when given with and without food in healthy participants.

Timeline

Start
2026-02-16
Primary completion
2026-04-02
Completion
2026-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule Oral
Subject Zibotentan Small molecule Oral

Indications

No indication recorded.